交易 Vir Biotechnology VIR

出售
 买入

VirBiotechnology 实时图表

5m 15m 30m 1h 4h 1d 1w

金融票据基础知识

Weekly Search
Weekly
Daily
日期 关闭 更改 更改(%)： 开盘价 高 低

VirBiotechnology news

最新新闻

显示更多
Noah Lee 2025 Aug 04, 02:20

Trump's Nuclear Rhetoric: Just a Diversion or Real Escalation?

Emma Rose 2025 Aug 04, 01:20

India Defies Trump's Threats, Continues Russian Oil Imports: Energy Security vs. Geopolitics

Sophia Claire 2025 Aug 04, 01:20

Trump's Tariffs on Switzerland: Recession Fears and Potential Deal Adjustments

Bank of England BoE
Tommy Yap 2025 Aug 02, 21:00

Week Ahead: Interest Rate Decisions from BoE in Focus

Forex Indices
Noah Lee 2025 Aug 02, 00:20

Market Review: Trump Tariffs, Fed Rate Hike Expectations, and Mixed Economic Data

Noah Lee 2025 Aug 01, 23:20

Market Review: Trump Tariffs, Fed Policy, Digital Assets, and Key Developments

Ava Grace 2025 Aug 01, 15:20

OPEC+ at a Crossroads: Production Hike and Future Market Challenges

Sophia Claire 2025 Aug 01, 14:20

US Job Growth Slows: Implications for the Federal Reserve

信息

点差

0.05

点差(%)

0.9960 %

杠杆

1:10

隔夜利息（买入）

-0.0597 %

隔夜利息（卖出）

-0.0292 %

币种

USD

交易时间

市场关闭

星期一

13:31 - 19:59

星期二

13:31-19:59

星期三

13:31-19:59

星期四

13:31-19:59

星期五

13:31-19:59

分析和统计

开盘价

---

昨收

---

52 周高点/低点

--- – ---

市值

695337152

在外流通股份

138238000

财报日（下一）

0000-00-00

股息收益率

除息日

远期年度股息率

0

远期年股息率

0

每股收益

-4.23

详细了解此金融票据

Vir Biotechnology Vir Biotechnology Inc
Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors.The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). It has grant agreements with Gates Foundation; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.

相关金融票据

资产
出售
买入
更改(%)：

立即交易

立即交易

立即交易

立即交易
相关金融票据

latest_education_articles

显示更多
Markets.com Support Team 2024 Nov 29, 03:00

如果你在 2010 年以每枚 $0.10 投資了 $100 的比特幣，今天您的資產將高達驚人的 9,570 萬美元！

Markets.com Support Team 2024 Nov 20, 17:00

狗狗幣的瘋狂旅程

Markets.com Support Team 2024 Nov 08, 17:00

交易員趨勢：狗狗幣

Trustpilot